IP Library Patent Application 10530209
Patent Application
App. No. 10/530,209

Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/530,209
Abstract

A method of reducing the serum level in a mammal of any one more cholesterol, low density lipoprotein (LDL) cholesterol relative to high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, apolipoprotein B, and triglycerides by the ingestion of a composition containing β-casein A 2 . A dietary supplement formed by the addition of β-casein to a food or drink for human consumption where the β-casein is comprised of at least 95% β-casein A 2 , preferably solely β-casein A 2 .

Claims (29)

1 . A method of reducing the serum level in a mammal of any one or more of the following:

a) cholesterol;

b) low density lipoprotein (LDL) cholesterol relative to high density lipoprotein (HDL) cholesterol;

c) low density lipoprotein (LDL) cholesterol;

d) very low density lipoprotein (VLDL) cholesterol;

e) apolipoprotein B; and

f) triglycerides

by the ingestion of a composition containing β-casein where the β-casein is comprised of at least 95% β-casein A 2 .

2 . A method as claimed in claim 1 where the β-casein is comprised solely of β-casein A 2 .

3 . A method for treating any disease or disorder associated with mammalian serum total cholesterol levels, LDL cholesterol levels, apolipoprotein B levels, or triglyceride levels by the ingestion of a composition containing β-casein where the β-casein is comprised of at least 95% β-casein A 2 .

4 . A method as claimed in claim 3 where the disease or disorder is selected from hypercholesterolemia hyperlipidemia, and atherosclerosis.

5 . A method as claimed in claim 1 where the composition is a food or food product.

6 . A method as claimed in claim 5 where the food or food product is milk or a product containing or processed from milk.

7 . A method as claimed in claim 1 where the composition is a dietary supplement.

8 . A method as claimed in claim 7 where the dietary supplement is a nutriceutical which is ingested for optimizing any one or more of the group consisting of performance during exercise, weight loss, weight gain, muscle building, and muscle repair.

9 . A method as claimed in claim 1 where the composition is milk containing β-casein where the β-casein is comprised of at last 95% β-casein A 2 .

10 . A method as claimed in claim 9 where the β-casein is comprised solely of β-casein A 2 .

11 . A method as claimed in claim 1 where the composition has been formed by the addition of an amount of β-casein A 2 sufficient to alter serum cholesterol levels and/or serum triglyceride levels in a human.

12 . A method as claimed in claim 1 where the β-casein A 2 is obtained from the milk of bovine cattle or from the milk of yaks, buffalo, sheep or goats.

13 . The use of β-casein A 2 in the manufacture of a composition for reducing the serum level in a mammal of any one or more of the following:

a) cholesterol;

b) low density lipoprotein (LDL) cholesterol relative to high density lipoprotein (HDL) cholesterol;

c) low density lipoprotein (LDL) cholesterol;

d) very low density lipoprotein (VLDL) cholesterol;

e) apolipoprotein B; and

f) triglycerides

14 . A dietary supplement formed by the addition of β-casein to a food or drink for human consumption where the β-casein is comprised of at least 95% β-casein A 2 .

15 . A dietary supplement as claimed in claim 13 where the β-casein is comprised solely of β-casein A 2 .

16 . A dietary supplement as claimed in claim 13 where the β-casein A 2 is obtained from the milk of bovine cattle or from the milk of yaks, buffalo, sheep or goats.

Assignments (2)
CHANGE OF NAME Recorded Nov 13, 2014
From: A2 CORPORATION LIMITED
To: THE A2 MILK COMPANY LIMITED
Reel/Frame 034229/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2005
From: CAMPBELL, JULIE HAZEL; TAILFORD, KRISTY ANN; MCLACHLAN, ULRIKE (LEGAL REPRESENTATIVE OF MCLACHLAN, CORAN NORMAN STUART-DECEASED)
To: A2 CORPORATION LIMITED
Reel/Frame 017033/0382 →